Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 20

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 20
---
 and believes that it is not exposed to any significant credit risk in cash and cash equivalents.
Bank failures, events involving limited liquidity, defaults, non-performance, or other adverse developments that affect financial institutions,
or concerns or rumors about such events, may lead to liquidity constraints. In 2023, certain U.S. government banking regulators took
steps to intervene in the operations of certain financial institutions due to liquidity concerns, which caused general heightened uncertainties
in financial markets. While previous bank failures have not had a material direct impact on the Company’s operations, if further
liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions,
the Company’s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse
effect on its business, financial condition and results of operations.

We are currently subject to securities class action litigation and may be subject to similar or other litigation in the future, all of which will require significant management time and attention, result in significant legal expenses and may result in unfavorable outcomes, which may have a material adverse effect on our business, operating results and financial condition, and negatively affect the price of our Common Stock.

We are, and may in the future become, subject
to various legal proceedings and claims that arise in or outside the ordinary course of business. For example, On January 19, 2024, a
purported shareholder class action complaint, captioned Eric Olmstead v. BioVie Inc. et al., No. 3:24-cv-00035, was filed in the
U.S. District Court for the District of Nevada, naming the Company and certain of its officers as defendants. On February 22, 2024, a
second, related putative securities class action was filed in the same court asserting similar claims against the same defendants, captioned
Way v. BioVie Inc. et al., No. 2:24-cv-00361. On April 15, 2024, the court consolidated these two actions under the caption In re BioVie Inc. Securities Litigation, No. 3:24-cv-00035, appointed the lead plaintiff, and approved selection of the lead counsel.
On June 21, 2024, the lead plaintiff filed an amended complaint, alleging that the defendants made material misrepresentations and/or
omissions of material fact relating to the Company’s business, operations, compliance, and prospects, including information related